Cardio Diagnostics Holdings, Inc. announced new partnerships with seven provider organizations, expanding the reach of its AI-driven precision cardiovascular medicine tests. These new partners span various regions and medical specialties, including the Midwest, Southwest, and Northeast.
The expansion highlights the growing adoption of the company's Epi+Gen CHD and PrecisionCHD blood tests, which are designed to transform the prevention, detection, and management of coronary heart disease. Integrating these tests allows providers to leverage advanced genetic and epigenetic technology for actionable insights.
These partnerships underscore the increasing recognition of the value of precision cardiovascular medicine in clinical settings. Equipping practices with these tests aims to enhance patient care, drive better outcomes, and make precision cardiovascular medicine more accessible.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.